Clinical Trial Update: Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating glofitamab in combination with rituximab or obinutuzumab plus CHOP for Richter syndrome; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Richter Syndrome

Drugs mentioned

• Adriamycin (doxorubicin)
• Columvi (glofitamab)
• Cytoxan (cyclophosphamide)
• Deltasone (prednisone)
• Gazyva (Obinutuzumab)
• Oncovin (vincristine)
• Rituxan (rituximab)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: Richter Syndrome | Phase 2 | Status: RECRUITING